浩歐博(688656.SH)下屬公司獲得醫療機構執業許可證
格隆匯11月29日丨浩歐博(688656.SH)公佈,近日,公司全資下屬公司成都温江浩歐博過敏專科門診部有限公司收到經四川省成都市温江區衞健局審核批准、四川省成都市温江區行政審批局簽發的《中華人民共和國醫療機構執業許可證》。
診療科目:內科;免疫學專業;變態反應專業/醫學檢驗科;臨牀體液、血液專業;臨牀免疫、血清學專業/醫學影像科;X 線診斷專業。
公司將依託在過敏診斷領域的核心優勢技術,建設線下過敏實體專科門診部,並依託該實體門診部建設線上互聯網醫院,從而為廣大過敏患者提供快捷、精準的過敏檢測和後續的診療、慢病管理等服務,讓過敏檢測更廣泛地惠及患者。上述許可證的取得,豐富了公司產品銷售渠道,有利於公司市場拓展,提升了公司核心競爭力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.